Turning Point Therapeutics Inc. (TPTX) Misses Q3 EPS by 7c

Turning Point Therapeutics Inc. (NASDAQ: TPTX) reported Q3 EPS of ($1.34), $0.07 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $460 thousand.

For earnings history and earnings-related data on Turning Point Therapeutics Inc. (TPTX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Rothschild Redburn Upgrades Apple (AAPL) to Buy
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight